<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01521702</url>
  </required_header>
  <id_info>
    <org_study_id>NEOPAC / IPC 2011-002</org_study_id>
    <nct_id>NCT01521702</nct_id>
  </id_info>
  <brief_title>NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer</brief_title>
  <acronym>NEOPAC</acronym>
  <official_title>Adjuvant Gemcitabine Versus NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer: a Randomized Multicenter Phase III Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the additional value of neoadjuvant chemotherapy to the
      standard treatment for resectable pancreatic cancer (surgery + adjuvant chemotherapy).

      This study will be performed in compliance with the study protocol, GCP (good clinical
      practice) and the applicable regulatory requirements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>from date of randomization until date of progression, assessed up to 5 years</time_frame>
    <description>period from study inclusion until the date of recurrence or surgery (in case of unresectability at surgical exploration).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>histology</measure>
    <time_frame>at 6 months</time_frame>
    <description>histological response,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until date of death, assessed up to 5 years</time_frame>
    <description>time from date of inclusion to date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication</measure>
    <time_frame>until 6 months</time_frame>
    <description>complication rates after surgery,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After initial staging laparoscopy, Neoadjuvant chemotherapy consists of four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours, modified from the Louvet protocol11).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy</intervention_name>
    <description>four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery and Adjuvant chemotherapy</intervention_name>
    <description>surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.</description>
    <arm_group_label>surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resectable adenocarcinoma of the pancreatic head (requiring duodeno-pancreatectomy)

          -  T1-3, Nx, M0 (UICC 6th version, 2002)

          -  infiltration of the portal vein (&lt;180°) is not an exclusion criterion

          -  cytologic or histologic confirmation of adenocarcinoma

          -  age &gt;18 years

          -  written informed consent

        Exclusion Criteria:

          -  contraindication for Whipple procedure

          -  an infiltration &gt;180° of the portal vein

          -  abutment of the tumor to the superior mesenteric artery

          -  infiltration of the superior mesenteric artery or the celiac trunk

          -  chronic neuropathy &gt; grade 2

          -  WHO performance score &gt;2

          -  uncorrectable cholestasis (bilirubin &gt; 100mmol/l despite drainage attempts for more
             than four weeks prior to inclusion)

          -  female patients in child bearing age not using adequate contraception (oral or
             subcutaneous contraceptives, intrauterine pessars (IUP), condoms)

          -  pregnant or lactating women

          -  mental or organic disorders which could interfere with giving informed consent or
             receiving treatments

          -  Second malignancy diagnosed within the past 5 years, except non-melanomatous skin
             cancer or non-invasive cervical cancer

          -  percutaneous biopsy of the primary tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Luc RAOUL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr</url>
    <description>official web site of the sponsor</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>January 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2012</study_first_posted>
  <last_update_submitted>March 19, 2015</last_update_submitted>
  <last_update_submitted_qc>March 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma</keyword>
  <keyword>pancreatic head</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

